Page 17 - Bio Developments News Today

Aragen, a provider of contract research, development, and manufacturing services for the pharmaceutical industries, has commissioned its new formulations manufacturing facility in Hyderabad, India.

Charles River has granted its clients the ability to conduct preclinical cancer research using ITCC-P4’s collection of 400 annotated pediatric cancer models.

Scientists may have identified the biggest breakthrough in cervical cancer treatment in 20 years, giving patients existing drugs before standard radiotherapy treatment.

Cellipoint Bioservices signed an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine.

Researchers at the UK Dementia Research Institute have developed a new form of deep brain stimulation that does not require surgery and could provide an alternative treatment option for debilitating brain diseases such as Alzheimer’s.

Clerkenwell Health is partnering with Transcend Therapeutics to trial the use of methylone in patients with severe post-traumatic stress disorder (PTSD).

Accessing various sponsor technology systems in a clinical trial can be a laborious and complex process. Site vendors often have to juggle various links and platforms to access important information and manage large lists of credentials across studies and partners.

Biotherapeutics, a San Francisco based company developing a platform for cancer immunotherapy, will present its phase 1/2 dose escalation study of BDC-1001 at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain.

Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.

SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has partnered with Spark Therapeutics to develop a gene therapy for an inherited retinal disease.